Year All2024202320222021202020192018201720162014201320112010 April 24, 2024 Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 April 16, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants April 1, 2024 Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing March 25, 2024 Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist March 11, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants March 6, 2024 Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences February 22, 2024 Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan February 22, 2024 Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update February 8, 2024 Rhythm Pharmaceuticals Announces New Employment Inducement Grants February 7, 2024 Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
April 24, 2024 Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
March 25, 2024 Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
February 22, 2024 Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024 Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 7, 2024 Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
